NPT-2042 is under clinical development by NeuroPro Therapeutics and currently in Phase I for Seizures. According to GlobalData, Phase I drugs for Seizures have a 94% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NPT-2042’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
NPT-2042 overview
NPT-2042 is under development as an adjunct anti seizure treatment for patients with medically intractable epilepsy. It is administered as soft-gelatin capsules administered through orally route.
NeuroPro Therapeutics overview
NeuroPro Therapeutics is a North Carolina-based stealth biotechnology company. NeuroPro Therapeutics is headquartered in Bahama, North Carolina, the US.
For a complete picture of NPT-2042’s drug-specific PTSR and LoA scores, buy the report here.
Source link
#NPT2042 #NeuroPro #Therapeutics #Seizures #Likelihood #Approval
